Literature DB >> 1707760

FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes.

C S Lin1, R C Boltz, J J Siekierka, N H Sigal.   

Abstract

This report compares the ability of cyclosporin A and FK-506 to inhibit human T cell activation triggered via cell surface molecules that utilize different intracellular processes. We stimulated highly purified peripheral blood T lymphocytes with mitogens (Con A and PHA), ionomycin + PMA, or monoclonal antibodies specific for cell surface antigens involved in activation (CD2, CD3, CD28) either in combination with each other or in conjunction with PMA. Using measurements of the proliferative response, IL-2 production, and changes in intracellular Ca2+ ([Ca2+]i), we demonstrate that FK-506 exerts its inhibitory effect on early events of T-cell activation in a manner indistinguishable from that of CsA. An important finding in this study is the strict correlation between those activation pathways that are inhibited by FK-506 and CsA and the requirement that the sensitive pathways induce a measurable rise in [Ca2+]i. This correlation held even for the CD28/CD2 pathway which was previously shown to be calcium-independent; however by employing FACS analysis of [Ca2+]i within individual cells, a subset of cells activated via CD28/CD2 was found to respond with a measurable rise in [Ca2+]i. We also noted that the proliferative response induced by certain stimuli, such as ionomycin + PMA and PHA + PMA, was partially resistant to FK-506 and CsA, while IL-2 production was completely suppressed. The partial FK-506/CsA-resistance of these responses was shown to be determined by the amount of PMA added to the cultures. We conclude from our investigations that FK-506 and CsA inhibit highly similar signal transduction pathways in human T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707760     DOI: 10.1016/0008-8749(91)90103-i

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  22 in total

1.  Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects.

Authors:  Yong Zeng; Yi-jing He; Fu-yuan He; Lan Fan; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

Review 2.  Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin.

Authors:  J J Siekierka
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

3.  Light-regulated, tissue-specific immunophilins in a higher plant.

Authors:  S Luan; M W Albers; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

4.  TGF beta 1 inhibits Ca2+-calcineurin-mediated activation in thymocytes.

Authors:  Ramireddy Bommireddy; Ilona Ormsby; Moying Yin; Gregory P Boivin; George F Babcock; Thomas Doetschman
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

5.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system.

Authors:  Y Elitsur; X Liu; J Dosescu; J A Moshier
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

7.  Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

8.  Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.

Authors:  T Thomas; U B Gunnia; E J Yurkow; J R Seibold; T J Thomas
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

9.  Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin.

Authors:  H Luo; H Chen; P Daloze; G St-Louis; J Wu
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 10.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.